Immune checkpoint inhibitors(ICIs)have become a new hope for the treatment of lung cancer.ICIs can significantly improve the prognosis of patients with advanced lung cancer or perioperative treatment.However,with the widespread use of ICIs,it also brings organ-specific immune-related adverse events(irAEs).ICIs may affect all systems of the body,among which immune checkpoint inhibitor-related pneumonia(CIP)caused by ICIs therapy refers to new infiltration in chest imaging after ICIs treatment,dyspnea and/or other respiratory signs/symptoms except for new pulmonary infection or tumor progression.At present,there are many reports about the mechanism of occurrence and development of CIP and clinical management strategies.This article mainly reviews the risk factors,pathogenesis,coping strategies,and challenges related to CIP.
万方数据
维普
